Activation of WNT/b-catenin signaling results in resistance to PI3K/mTOR dual inhibitor in co-existing KRAS and PIK3CA mutant colorectal cancer cells

被引：0
|
作者：
Park, Ye-Lim
Kim, Hwang-Phill
Cheon, Seul-Ki
Kang, Jun-Kyu
Lim, Yoojoo
Song, Sang-Hyun
Han, Sae-Won
Kim, Tae-you
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-5214
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5214
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Analysis of PIK3CA mutations and PI3K signaling proteins as prognostic biomarkers for advanced gastric cancer
    Nishizuka, Satoshi S.
    Ito, Chie
    Kume, Kohei
    Iwaya, Takeshi
    Koeda, Keisuke
    Sasaki, Akira
    CANCER RESEARCH, 2017, 77
  • [32] NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations
    Serra, Violeta
    Markman, Ben
    Scaltriti, Maurizio
    Eichhorn, Pieter J. A.
    Valero, Vanesa
    Guzman, Marta
    Luisa Botero, Maria
    Llonch, Elisabeth
    Atzori, Francesco
    Di Cosimo, Serena
    Maira, Michel
    Garcia-Echeverria, Carlos
    Lluis Parra, Josep
    Arribas, Joaquin
    Baselga, Jose
    CANCER RESEARCH, 2008, 68 (19) : 8022 - 8030
  • [33] PIK3CA mutation confers resistance to chemotherapy in triple-negative breast cancer by inhibiting apoptosis and activating the PI3K/AKT/mTOR signaling pathway
    Hu, Huayu
    Zhu, Junyong
    Zhong, Yuting
    Geng, Rui
    Ji, Yashuang
    Guan, Qingyu
    Hong, Chenyan
    Wei, Yufan
    Min, Ningning
    Qi, Aiying
    Zhang, Yanjun
    Li, Xiru
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (05)
  • [34] Unilateral focal palmoplantar keratoderma associated with a postzygotic variant in PIK3CA and activation of the PI3K/AKT/mTOR pathway
    Gong, Zhuoqing
    Peng, Sha
    Wang, Huijun
    Jiang, Xingyuan
    Ke, Xiaoping
    Lin, Zhimiao
    EUROPEAN JOURNAL OF DERMATOLOGY, 2024, 34 (03) : 287 - 293
  • [35] The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in PIK3CA-Mutant Breast Cancer Brain Metastases
    Ippen, Franziska M.
    Alvarez-Breckenridge, Christopher A.
    Kuter, Benjamin M.
    Fink, Alexandria L.
    Bihun, Ivanna, V
    Lastrapes, Matthew
    Penson, Tristan
    Schmidt, Stephen P.
    Wojtkiewicz, Gregory R.
    Ning, Jianfang
    Subramanian, Megha
    Giobbie-Hurder, Anita
    Martinez-Lage, Maria
    Carter, Scott L.
    Cahill, Daniel P.
    Wakimoto, Hiroaki
    Brastianos, Priscilla K.
    CLINICAL CANCER RESEARCH, 2019, 25 (11) : 3374 - 3383
  • [36] The PI3K inhibitor, taselisib, has a unique mechanism of action that leads to enhanced potency in PIK3CA mutant models
    Song, Kyung W.
    Edgar, Kyle A.
    Kirkpatrick, Donald S.
    Phu, Lilian
    Schmidt, Stephen
    Nannini, Michelle
    Hong, Rebecca
    Cheng, Eric
    Crocker, Lisa
    Young, Amy
    Sampath, Deepak
    Friedman, Lori
    CANCER RESEARCH, 2017, 77
  • [37] The PI3K inhibitor, taselisib, has enhanced potency in PIK3CA mutant models through a unique mechanism of action
    Friedman, L. S.
    Edgar, K. A.
    Song, K.
    Schmidt, S.
    Kirkpatrick, D. S.
    Phu, L.
    Nannini, M. A.
    Hong, R.
    Cheng, E.
    Crocker, L.
    Young, A.
    Sampath, D.
    CANCER RESEARCH, 2017, 77
  • [38] Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR
    Belmont, Peter J.
    Jiang, Ping
    Mckee, Trevor D.
    Xie, Tao
    Isaacson, Jason
    Baryla, Nicole E.
    Roper, Jatin
    Sinnamon, Mark J.
    Lee, Nathan V.
    Kan, Julie L. C.
    Guicherit, Oivin
    Wouters, Bradly G.
    O'Brien, Catherine A.
    Shields, David
    Olson, Peter
    VanArsdale, Todd
    Weinrich, Scott L.
    Rejto, Paul
    Christensen, James G.
    Fantin, Valeria R.
    Hung, Kenneth E.
    Martin, Eric S.
    SCIENCE SIGNALING, 2014, 7 (351)
  • [39] PI3K signaling pathway is activated by PIK3CA mRNA overexpression and copy gain in prostate tumors, but PIK3CA, BRAF, KRAS and AKT1 mutations are infrequent events
    Agell, Laia
    Hernandez, Silvia
    Salido, Marta
    de Muga, Silvia
    Juanpere, Nuria
    Arumi-Uria, Montserrat
    Menendez, Silvia
    Lorenzo, Marta
    Lorente, Jose A.
    Serrano, Sergio
    Lloreta, Josep
    MODERN PATHOLOGY, 2011, 24 (03) : 443 - 452
  • [40] Positive correlation between transcriptomic stemness and PI3K/AKT/mTOR signaling scores in breast cancer, and a counterintuitive relationship with PIK3CA genotype
    Madsen, Ralitsa
    Erickson, Emily
    Rueda, Oscar
    Robin, Xavier K.
    Caldas, Carlos
    Toker, Alex
    Semple, Robert
    Vanhaesebroeck, Bart
    PLOS GENETICS, 2021, 17 (11):
12345